In last trading session, Fulcrum Therapeutics Inc (NASDAQ:FULC) saw 1.22 million shares changing hands with its beta currently measuring 2.29. Company’s recent per share price level of $9.67 trading at -$0.12 or -1.23% at ring of the bell on the day assigns it a market valuation of $598.96M. That closing price of FULC’s stock is at a discount of -41.68% from its 52-week high price of $13.70 and is indicating a premium of 76.73% from its 52-week low price of $2.25. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.61 million shares which gives us an average trading volume of 690.82K if we extend that period to 3-months.
Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information
Upright in the red during last session for losing -1.23%, in the last five days FULC remained trading in the red while hitting it’s week-highest on Monday, 03/18/24 when the stock touched $9.67 price level, adding 15.77% to its value on the day. Fulcrum Therapeutics Inc’s shares saw a change of 43.26% in year-to-date performance and have moved -14.88% in past 5-day. Fulcrum Therapeutics Inc (NASDAQ:FULC) showed a performance of 1.26% in past 30-days. Number of shares sold short was 3.2 million shares which calculate 5.14 days to cover the short interests.
Fulcrum Therapeutics Inc (FULC) estimates and forecasts
Statistics highlight that Fulcrum Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 136.43% of value to its shares in past 6 months, showing an annual growth rate of -10.69% while that of industry is 12.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -7.30% in the current quarter and calculating -15.80% decrease in the next quarter. This year revenue growth is estimated to fall -31.60% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $360k for the same. And 7 analysts are in estimates of company making revenue of $370k in the next quarter that will end on Jun 2024.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 1.09% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -9.83% while estimates for its earnings growth in next 5 years are of 14.30%.
FULC Dividends
Fulcrum Therapeutics Inc is more likely to be releasing its next quarterly report between May 13 and May 17 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders
Insiders are in possession of 1.38% of company’s total shares while institution are holding 99.10 percent of that, with stock having share float percentage of 100.49%. Investors also watch the number of corporate investors in a company very closely, which is 99.10% institutions for Fulcrum Therapeutics Inc that are currently holding shares of the company. RA Capital Management, L.P. is the top institutional holder at FULC for having 11.61 million shares of worth $112.27 million. And as of Dec 30, 2023, it was holding 18.74% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 5.68 million shares on Dec 30, 2023. The number of shares represents firm’s hold over 9.18% of outstanding shares, having a total worth of $54.97 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 1.69 million shares of worth $16.39 million or 2.74% of the total outstanding shares. The later fund manager was in possession of 1.56 million shares on Jan 30, 2024, making its stake of worth around $15.07 million in the company or a holder of 2.52% of company’s stock.
